Trial Profile

Long-term Follow-up of Subjects With Childhood Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 29 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elivaldogene autotemcel (Primary)
Indications Adrenoleucodystrophy
Focus Adverse reactions; Therapeutic Use
Sponsors Genetix Biotherapeutics

Most Recent Events

18 Sep 2025 According to Bluebird bio media release, Bluebird bio has changed its name to Genetix Biotherapeutics.
17 Aug 2020 According to a bluebird bio media release, data will be presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2020).
19 May 2020 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com